16 Results Found
Our commitment to HIV treatments and prevention through the years
HIV (human immunodeficiency virus) continues to be a major public health threat. The virus can lead to AIDS. Since 1985, our company has been engaged in research and development (R&D) efforts in the prevention and treatment of HIV. Over the years, our scientists have made significant discoveries that changed the way HIV is treated. Here […]
World AIDS Day 2025: Research remains key
>> Go to all press releases World AIDS Day 2025: Research remains key Lucerne, December 1, 2025 – World AIDS Day was launched in 1988.1 Held every year on December 1 since then, it serves as a reminder that the human immunodeficiency virus, or HIV for short, continues to pose a challenge to public health.4 At […]
CAPVAXIVE – Publication of clinical trial results
Publication of clinical trial results The information given below and the relevant links to the clinical data fulfil the requirements of Articles 71-73 of the Ordinance on Therapeutic Products (Therapeutic Products Ordinance, TPO). They supplement the information published in association with the Swiss marketing authorisation for the medicinal product.. CAPVAXIVE® CAPVAXIVE® (Pneumococcal 21-valent conjugate vaccine), […]
https://www.msd.ch/en/capvaxive-veroffentlichung-der-ergebnisse-klinischer-studien/
HIV Our legacy in innovative HIV science continues We remember when HIV was one of society’s most daunting challenges, when millions of people lost their lives to the devastating AIDS epidemic. Our scientists embarked on an urgent mission to unravel and understand the virus, which led to groundbreaking research in HIV. We are still driven […]
https://www.msd.ch/en/home/about-us/areas-of-focus/infectious-diseases/
Our purpose: We use the power of leading-edge science to save and improve lives around the world We focus on disease areas with unmet medical need Find out more about our main areas of focus. CH-NON-00617, 03/2025
Clinical trials in Switzerland
MSD’s clinical study program in Switzerland (as of 07/2025) (published on www.clinicaltrials.gov) Click here for an overview of Switzerland-wide studies that are seeking participants www.kofam.ch CH-NON-00136, 08/2025
https://www.msd.ch/en/home/research/clinical-trials/clinical-trials-in-switzerland/
Launch of the HPV awareness campaign „Against HPV. Against cancer. For life.“
>> Go to all press releases Lucerne, November 7th, 2023 – 50% of all (cancer) diseases caused by infection in developed countries are related to HPV. At the same time, 85–90% of all people become infected with human papilloma viruses (HPV) over the course of their lives (see figure). Most sexually active men and women […]
https://www.msd.ch/en/news/launch-of-the-hpv-awareness-campaign-against-hpv-against-cancer-for-life/
MSD tradition of Diversity Diversity and Inclusion are not mere words for us – they embody the reason we are able to realize our corporate purpose: We harness the power of cutting-edge research to save and improve lives around the world. MSD as an employer Would you like to work with us to further develop […]
>> Go to all press releases Lucerne, June 5 2023 – MSD Switzerland (Merck Sharp & Dohme AG) is celebrating the 60th anniversary of its first Swiss subsidiary in Lucerne this year. At the same time, the company confirms its commitment to the site and the Lucerne region. With five subsidiaries in the country, including […]
Our Milestones in Switzerland MSD Switzerland – Who We Are Today As of 2025 we will be operating in the Rösslimatt area of Lucerne We are pleased to be bringing together three of MSD’s five branches in the Rösslimatt area. More information CH-NON-02244, 05/2025
